Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
iCAD
MedTech
RadNet to absorb mammography AI developer iCad in $103M deal
The all-stock transaction is valued at about $103 million, or a 98% premium over iCad’s recent share price.
Conor Hale
Apr 16, 2025 2:05pm
Mammography AI maker iCad lays off 28% of workers
Mar 27, 2023 11:48am
iCAD's AI catches more breast cancers in real-world study
May 20, 2022 10:31am
iCAD's AI-based 3D mammogram support tool earns FDA nod
Mar 27, 2017 9:28am
